Announcements Trials
Browse Landscape

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Breast Neoplasms 19Prostatic Neoplasms 14Carcinoma, Non-Small-Cell Lung 9Pancreatic Neoplasms 8Neoplasms 8Colorectal Neoplasms 8Melanoma 6Colonic Neoplasms 6Esophageal Neoplasms 5Stomach Neoplasms 4Rectal Neoplasms 4Precancerous Conditions 4Myelodysplastic Syndromes 4Lymphoma 4Lung Neoplasms 4Liver Neoplasms 4Head and Neck Neoplasms 4Barrett Esophagus 4Squamous Cell Carcinoma of Head and Neck 3Salivary Gland Neoplasms 3Ovarian Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Mouth Neoplasms 3Kidney Neoplasms 3Gastrointestinal Neoplasms 3Gastroesophageal Reflux 3Gastritis, Atrophic 3Adenocarcinoma Of Esophagus 3Uterine Cervical Neoplasms 2

Interventions

Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Pruritus × Biopsy × Clear all
NCT01801670 2015-01-27

Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study

Boston University

Withdrawn
DermatologicLymphoid

Mycosis Fungoides, Pruritus, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡